UPDATE: Lannett Says Will Transfer Production Of Finished Dosage Liquid Pharma Products To Its Carmel, New York Facility, Discontinue Manufacturing Of Less Profitable API Products, Rationalize API Product Development Program
Benzinga Newsdesk